GLPwatch
Papers (10401)
Page 32 of 174, ranked by citation count.
- Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.
- Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis.
- An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke.
- Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3β activity.
- Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity.
- Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats.
- Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.
- The effect of liraglutide on endothelial function in patients with type 2 diabetes.
- Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
- GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.
- Proteasome dysfunction mediates high glucose-induced apoptosis in rodent beta cells and human islets.
- Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.
- Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
- Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
- Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
- Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
- Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway.
- No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.
- Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review.
- Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
- Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.
- FLOW trial stopped early due to evidence of renal protection with semaglutide.
- Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis.
- Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy.
- Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.
- New and emerging drug molecules against obesity.
- Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
- Exenatide-induced acute pancreatitis.
- Liraglutide mitigates TNF-α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women.
- Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
- Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.
- Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats.
- Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.
- Liraglutide-induced acute kidney injury.
- Improvement of Transdermal Delivery of Exendin-4 Using Novel Tip-Loaded Microneedle Arrays Fabricated from Hyaluronic Acid.
- Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices.
- Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
- Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart.
- The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
- Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
- Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
- Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
- Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway.
- Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function.
- Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
- Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson's Disease.
- Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism.
- Liraglutide enhances insulin sensitivity by activating AMP-activated protein kinase in male Wistar rats.
- Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
- Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.
- Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP/PKA mediated down-regulation of MLC phosphorylation.
- Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway.
- Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety.
- Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts.
- Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
- GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity.
- Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.